C-reactive protein and cardiovascular disease risk: Still an unknown quantity?

Annals of Internal Medicine

Volumn 145, Issue 1, 2006, Pages 70-72

  Smith, George Davey ^a   Timpson, Nic ^a   Lawlor, Debbie A ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ATORVASTATIN; C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY ARTERY LIGATION; DISEASE MARKER; EDITORIAL; GENETIC VARIABILITY; HEART INFARCTION; HUMAN; HYPERTENSION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SOCIOECONOMICS; VITAMIN SUPPLEMENTATION; BLOOD; METABOLISM; METHODOLOGY; NOTE;

C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; HUMANS; RISK ASSESSMENT;

EID: 33745945458     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-145-1-200607040-00130     Document Type: Editorial

References (20)

1. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387-97.
2. Lawlor DA, Davey Smith G, Rumley A, Lowe GD, Ebrahim S. Associations of fibrinogen and C-reactive protein with prevalent and incident coronary heart disease are attenuated by adjustment for confounding factors. British Women's Heart and Health Study. Thromb Haemost. 2005;93:955-63.
3. Lagrand WK, Visser CA, Hermens WT, Niessen HW, Verheugt FW, Wolbink GJ, et al. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation. 1999;100:96-102.
4. Verma S, Devaraj S, Jialal I. Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosis. Circulation. 2006;113:2135-50.
5. Cook NR, Buring JE, Ridker PM. The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med. 2006;145:21-9.
6. Lloyd-Jones DM, Liu K, Tian L, Greenland P. Narrative review: assessment of C-reactive protein in risk prediction for cardiovascular disease. Ann Intern Med. 2006;145:35-42.
7. Davey Smith G, Egger M. Who benefits from medical interventions? [Editorial] BMJ. 1994;308:72-4.
8. May M, Lawlor DA, Brindle P, Patel R, Ebrahim S. Cardiovascular disease risk assessment in older women - can we improve on Framingham?: British Women's Heart and Health prospective cohort study. Heart. 2006.
9. Davey Smith G, Hart C, Blane D, Gillis C, Hawthorne V. Lifetime socioeconomic position and mortality: prospective observational study. BMJ. 1997;314:547-52.
10. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-78.
11. Scirica BM, Morrow DA. Is C-reactive protein an innocent bystander or proatherogenic culprit? The verdict is still out. Circulation. 2006;113:2128-34.
12. Davey Smith G, Ebrahim S. Folate supplementation and cardiovascular disease. Lancet. 2005;366:1679-81.
13. Davey Smith G, Ebrahim S. "Mendelian randomization": can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32:1-22.
14. Davey Smith G, Ebrahim S. Mendelian randomization: prospects, potentials, and limitations. Int J Epidemiol. 2004;33:30-42.
15. Davey Smith G, Lawlor DA, Harbord R, Timpson N, Rumley A, Lowe GD, et al. Association of C-reactive protein with blood pressure and hypertension: life course confounding and mendelian randomization tests of causality. Arterioscler Thromb Vasc Biol. 2005;25:1051-6.
16. Timpson NJ, Lawlor DA, Harbord RM, Gaunt TR, Day IN, Palmer LJ, et al. C-reactive protein and its role in metabolic syndrome: mendelian randomisation study. Lancet. 2005;366:1954-9.
17. Casas JP, Shah T, Cooper J, Hawe E, McMahon AD, Gaffney D, et al. Insight into the nature of the CRP-coronary event association using Mendelian randomization. Int J Epidemiol. 2006.
18. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20-8.
19. Pepys MB, Hirschfield GM, Tennent GA, Gallimore JR, Kahan MC, Bellotti V, et al. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature. 2006;440:1217-21.
20. Armani A, Becker RC. The biology, utilization, and attenuation of C-reactive protein in cardiovascular disease: part I. Am Heart J. 2005;149:971-6.